Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Perioperative targeted therapy for oncogene-driven NSCLC.

Lung cancer (Amsterdam, Netherlands) - 1 Oct 2022

Liu Si-Yang, Zhang Jia-Tao, Zeng Kang-Hui, Wu Yi-Long

Abstract excerpt

Targeted therapy has stepped into the perioperative treatment arena and launched a radical revolution in the treatment of early-stage oncogene-driven non-small-cell lung cancer (NSCLC). A series of practice-changing clinical trials has enriched the therapeutic perspectives of potentially curable NSCLC. While the CTONG1104 trial took the first step in investigating the adjuvant gefitinib - a first-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Gefitinib
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogenes

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 35644704
DOI: 10.1016/j.lungcan.2022.05.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Perioperative targeted therapy for oncogene-driven NSCLC.PMID 35644704Read ↗

Perioperative Therapy in Oncogene-Driven Non-Small Cell Lung Cancer: Current Strategies and Unanswered Questions.Semantic proximity Read ↗

Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.Semantic proximity Read ↗

Targeted Therapy in Early Stage Non-small Cell Lung Cancer.Semantic proximity Read ↗

Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making.Semantic proximity Read ↗

Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.Semantic proximity Read ↗

[Progress and Discussion of Perioperative Targeted Therapy in Patients with EGFR-mutated Resectable Non-small Cell Lung Cancer].Semantic proximity Read ↗

Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?Semantic proximity Read ↗

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Targeted therapeutic options in early and metastatic NSCLC-overview.Semantic proximity Read ↗

Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges.Semantic proximity Read ↗

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.Semantic proximity Read ↗

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.